Recently, LMH001 (Figure 1B) was presented as a new small-molecule p47phox/p22phox inhibitor able to reduce endothelial NOX2 activity and protect mice (but not p47phox knockout mice) from angiotensin II-induced vascular oxidative stress, hypertension and aortic aneurysm (Fan et al., 2022). Here, NCF1 is linked to hypertensive disorder.